 |
 |
Anne, There should be no more interaction between dopamine agonists and Tolcapone than with carbidopa. Like carbidopa, Tolcapone inhibits the conversion of L-dopa in the blood (where it does no good for PD symtoms). Bottom line: more L-dopa gets to the brain where itr is useful.. The dopamine agonists have a completely separate job, fooling the D receptors into thinking they are dopamine.. And then there are the MAOB inhibitors (i.e. Eldepryl) which inhibit the uptake of used dopamine, also making more available. These are the only groups of PD meds that affect the level of dopamine. The others, such as Amantadine, use other mechanisms to alleviate PD symptoms. Bruce 55/9 Sinemet CR, & Mirapex